U.S. Dollar Steadies Near October Lows as Rate Cut Expectations Keep Markets on Edge 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
CMOC to Acquire Equinox Gold’s Brazilian Mines in $1 Billion Deal to Expand Precious Metals Portfolio 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
Strategy Retains Nasdaq 100 Spot Amid Growing Scrutiny of Bitcoin Treasury Model 
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles 
Oil Prices Rebound as Trump Orders Blockade of Sanctioned Venezuelan Tankers 
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions 
Bank of Korea Downplays Liquidity’s Role in Weak Won and Housing Price Surge 
New Zealand Budget Outlook Shows Prolonged Deficits Despite Economic Recovery Hopes 
Bank of Japan Poised for Historic Rate Hike as Inflation Pressures Persist 
Asian Currencies Trade Sideways as Dollar Weakens Ahead of Key U.S. Data 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
Gold and Silver Surge as Safe Haven Demand Rises on U.S. Economic Uncertainty 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
Samsung Biologics is expanding its CMO or contract manufacturing organization business, and as part of its plans, it is constructing its very first overseas production plant in the United States.
On Monday, June 13, Samsung Biologics’ chief executive officer, John Rim, shared that they are considering several locations for the facility. He said that the strongest candidates for their CMO site are Texas, North Carolina, California, and Washington.
According to The Korea Herald, Samsung Biologics is looking into these places more because many of the major bio companies’ facilities are also operating in the mentioned US states. At this time, the company has not yet made any decision and carefully reviewing the areas to choose the best option.
“We are certainly expanding and the Plant 4 will begin partial operation in October, adding a 60,000-liter production capacity,” the Samsung Biologics’ CEO told the media during the press meeting for the 2022 BIO International Convention in San Diego, California. “By the second quarter of next year, it will have a 180,000-liter production capacity.”
While planning to build its first manufacturing plant abroad, Samsung Biologics has already set up its fourth factory in Songdo, Incheon, in South Korea. Once this facility starts operating at its full capacity, it is expected to boost production.
All in all, the four plants should produce 620,000 liters of products for around 30% of the global demand. It was said that Samsung Biologics’ Plant 4 currently has the biggest CMO production capacity in the world, with 256,000 liters of products in a single facility.
Rim revealed that they are also aiming to build the fifth and sixth factories in South Korea, and this is why they are buying more land in Incheon. The purchases were originally expected to be completed by the end of May, but the authorities could not sign the contract because the government officials who are in charge, which are the mayor and commissioner of the Incheon Free Economic Zone, have changed due to the local elections that was held earlier this month.
Finally, the Samsung Biologics chief said that they still plan to go ahead with the construction of Plant 5 and 6. However, they will not be monitoring the supply and demand trends to see if there is still a need to build more factories.
